• Mashup Score: 9
    Tolebrutinib versus Teriflunomide in Multiple Sclerosis | NEJM - 1 hour(s) ago

    Quick Take Video Summary from The New England Journal of Medicine — Tolebrutinib versus Teriflunomide in Multiple Sclerosis

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      Tolebrutinib is a BTK inhibitor that is being studied for the treatment of relapsing multiple sclerosis. Research findings from the GEMINI 1 and GEMINI 2 trials comparing tolebrutinib with teriflunomide are summarized in a new Quick Take video. https://t.co/kb7KTzJsjO https://t.co/1LbXH48PVm

  • Mashup Score: 11
    Nerandomilast in Patients with Progressive Pulmonary Fibrosis | NEJM - 3 hour(s) ago

    Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the progr…

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      Original Article: Nerandomilast in Patients with Progressive Pulmonary Fibrosis (FIBRONEER-ILD phase 3 trial) https://t.co/WLtx356sBv #ATS2025 | @atscommunity https://t.co/Irf3AXfoam

  • Mashup Score: 24
    As-Needed Albuterol–Budesonide in Mild Asthma | NEJM - 4 hour(s) ago

    As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to-seve…

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      Original Article: As-Needed Albuterol–Budesonide in Mild Asthma (BATURA trial) https://t.co/RaDXohRnGF #ATS2025 | @atscommunity https://t.co/kfkeMGFyN5

  • Mashup Score: 19
    An Evidence-Based Approach to Covid-19 Vaccination | NEJM - 5 hour(s) ago

    This article from the FDA compares broad U.S. recommendations on Covid vaccination with those from other countries and announces the adoption of an evidence-based approach to such recommendations.

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of DrJMarine
      DrJMarine

      Big news. Common sense, reason, science, and evidence-based medicine finally returning to US public health. @DrMakaryFDA @VPrasadMDMPH @US_FDA An Evidence-Based Approach to Covid-19 Vaccination | New England Journal of Medicine https://t.co/mLScMxUcjC

  • Mashup Score: 18
    Treatment of Pyelonephritis | NEJM - 7 hour(s) ago

    EFFECTIVE therapy for most bacterial infections has been developed since the advent of potent antimicrobial agents. Chronic pyelonephritis, however, has been notably refractory to permanent cure. A…

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      From the NEJM Archive: Treatment of Pyelonephritis — Bacterial, Drug and Host Factors in Success or Failure among 252 Patients (Original Article, May 20, 1965) https://t.co/jssYUB1fdD https://t.co/3JF7XsvnCS

  • Mashup Score: 3
    Smoldering Multiple Myeloma | NEJM - 23 hour(s) ago

    MULTIPLE myeloma is characterized by an increase of abnormal plasma cells in the bone marrow and monoclonal protein in the serum, often with osteolytic bone lesions. Its course is progressive: anem…

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Smoldering multiple myeloma [1980] - @RobertK68033234 & Greipp @NEJM https://t.co/maBa3mbrhS #mmsm 1st use of SMM term

  • Mashup Score: 234
    Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis | NEJM - 23 hour(s) ago

    Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopa…

    Source: www.nejm.org
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of NEJM
      NEJM

      Presented at #ATS2025: In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: https://t.co/gjXxPWFpyR @atscommunity https://t.co/9iLsOtHsiC

Load More